Last reviewed · How we verify
NCT03696901
Xydalba Utilization Registry in Germany
trial testing Xydalba in Bacterial Infections in 16 participants. Terminated before completion.
30 March 2020
Quick facts
| Lead sponsor | Correvio International Sarl |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 21 November 2018 |
| Primary completion | 30 March 2020 |
| Estimated completion | 7 April 2020 |
| Sites | 7 locations across Germany |
Drugs / interventions tested
- Xydalba — full drug profile →
Conditions studied
- Bacterial Infections — all drugs for Bacterial Infections →
Sponsor
Correvio International Sarl — full company profile →
Who can join
18 and older, any sex, with Bacterial Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational study will collect data on the use of the drug Xydalba® in daily clinical practice in Germany. Such observational studies are also referred to as registries. The sponsor of the study is Correvio International Sárl, based in Switzerland. Xydalba® contains the active substance dalbavancin, a remedy for a certain type of bacterial pathogens (so-called "gram positive bacteria") which cause the disease. Active ingredients against bacteria are also called antibiotics. Correvio wants to know which patients received the drug and how the disease went. The treatment places where you got Xydalba, ie clinic, intensive care unit or elsewhere should be recorded. In addition, it is important in this type of medication to track whether the pathogens are changing in any way. Any safety-relevant events (such as side effects) that have occurred during treatment should be investigated by the sponsor and submitted to the competent European authorities.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice.
Hanses F, Dolff S, Trauth J, Seimetz M, et al · · 2022 · cited 2× · PMID 35625206 · DOI 10.3390/antibiotics11050563
Verify or expand the search:
- PubMed search for NCT03696901
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Xydalba
Trials testing the same drug.
- NCT04298463 — Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI · completed
- NCT03726216 — Xydalba Utilization Registry in France · completed
Other recruiting trials for Bacterial Infections
Currently open trials in the same condition.
- NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
- NCT07104162 — A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal I · Phase 1 · recruiting
- NCT07207291 — Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers · Phase 1 · recruiting
- NCT07056881 — Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa · recruiting
- NCT06592586 — A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women · Phase 2, PHASE3 · active not recruiting
Other Correvio International Sarl trials
Trials by the same sponsor.
- NCT03726216 — Xydalba Utilization Registry in France · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03696901 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Correvio International Sarl
- Last refreshed: 17 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03696901.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing